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There is growing recognition that pedia-
tric research is needed to improve
pediatric medicine [1,2].Research guide-
lines try to accommodate this need by
allowing children to be enrolled in
research when it offers an appropriate
risk–beneﬁt proﬁle. These guidelines
allow children to undergo research in-
terventions that offer a compensating
potentialforclinicalbeneﬁt.Mostguide-
lines also allow children to undergo
research interventions that do not offer
a compensating potential for clinical
beneﬁt,providedtherisksareacceptably
low.
To implement this threshold on ac-
ceptable risks, review committees, known
variously as ethics review committees,
institutional review boards, or research
ethics committees (RECs), must make
three related assessments. They must
identify the research interventions in-
cluded in the study under review, deter-
mine which, if any, of the research
interventions fail to offer participants a
compensating potential for clinical bene-
ﬁt, and ensure that these interventions do
not pose excessive risks.
These steps, while vital to protecting
pediatric participants from excessive
risks, have not been systematically de-
scribed. This essay attempts to address
this gap by describing the assessment
appropriate for each of these three steps.
When Is It Acceptable to Expose
Children to Research Risks?
Pediatric research raises special ethical
concern because children cannot provide
their own informed consent. Because of
children’s increased vulnerability, pediatric
researchtypicallyrequiresthepermissionof
aparentorlegalguardian.Inaddition,most
guidelines placestrictlimits ontheresearch
risks to which children may be exposed.
Of greatest concern are research
interventions that pose risks but do not
offer participants a compensating poten-
tial for clinical beneﬁt. These interven-
tions pose ‘‘net’’ risks in the sense that
the risks to participating children exceed
the potential that the intervention will
provide them with clinical beneﬁt. One
might argue that children should not be
allowed to undergo interventions that
pose net risks on the grounds that it is
inappropriate to expose children to risks
for the beneﬁt of others. This approach
appears to have been adopted by per-
haps the ﬁrst systematic research guide-
lines, the German guidelines of 1931,
which stipulate that pediatric research
shall be prohibited if it ‘‘in any way
endangers the child’’ [3].
Prohibiting all pediatric
research that poses net
risks could cripple
society’s ability to
ensure medications are
safe and effective for
children.
Prohibiting all pediatric research that
poses net risks could cripple society’s
ability to ensure medications are safe
and effective for children [4,5]. For
example, the process of developing new
medicines often requires initial pharma-
cokinetic studies. These studies, necessary
for determining what dosage levels to use
in future efﬁcacy studies, typically do not
offer a potential for clinical beneﬁt that
compensates for the risks of participating
in the research. More recent guidelines
aim to protect children without preclud-
ing socially valuable research by allowing
children to undergo research interven-
tions when the net risks are acceptably
low. How should RECs implement this
requirement?
When Are Net Risks ‘‘Acceptably’’
Low?
Leave to the judgment of the REC.
Someguidelinesleavethedetermination
of when net risks are acceptably low to
the judgment of the reviewing REC (see
Table 1). The Kenyan [6] and Indian
Council of Medical Research [7] guide-
lines simply direct RECs to ensure that
the risks presented by interventions
that will not beneﬁt participating chil-
dren are low. The Council of Europe
and the United Kingdom’s Medical
Research Council provide somewhat
more guidance, stating that research
qualiﬁes as ‘‘minimal’’ risk if ‘‘it is to be
expected that it will result, at the most,
in a very slight and temporary negative
impact on the health of the person
concerned’’ [8,9].
Mandating that risks must be low
without providing a standard to make
this assessment may not provide sufﬁ-
cient guidance. The Council of Eu-
rope’s guidelines, for example, leave it
to the judgment of RECs to determine
when a potential harm qualiﬁes as
‘‘slight.’’ Unfortunately, psychological
research demonstrates that individuals
make systematic errors when they rely
on their own perceptions to assess risks
[10–12], suggesting that RECs need
more guidance.
Net risks no greater than risks of
routine examinations. As e c o n da p -
proach deﬁnes acceptably low risks
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tions and tests. The Council for Interna-
tional Organizations of Medical
Sciences (CIOMS) takes this approach,
deeming research interventions accept-
able when the risks ‘‘do not exceed
those associated with routine medical
and psychological examination of such
persons’’ [13]. Similarly, the Canadian
Tri-Council report states that risks
qualify as minimal when potential par-
ticipants can reasonably be expected to
regard them as ‘‘no greater than those
encountered by the subject in those
aspects of his or her everyday life that
relate to the research’’ [14].
Although the Canadian deﬁnition is
not as clear as one might hope, both
standards appear to allow patients
who undergo risky examinations as
part of their medical care to be
exposed to greater research risks than
healthy children. To avoid taking
advantage of sick children in this
way, several commentators deﬁne min-
imal risks based on the risks posed by
routine examinations for healthy chil-
dren [15,16].
The Bright Futures guidelines, en-
dorsed by the American Academy of
Pediatrics (AAP), recommend that
healthy children be assessed for height,
weight, head circumference, vision, and
hearing [17]. The only invasive exami-
nation recommended for healthy chil-
dren is a single heel stick at birth to
screen for metabolic disorders. In
practice, then, the healthy-child ver-
sion of the routine examinations stand-
ard avoids the potential to exploit sick
children by essentially precluding re-
search that poses any net risks. Fur-
thermore, children in some countries
do not undergo routine medical exami-
nations, leaving it unclear how this
standard would be applied in those
countries.
Net risks no greater than risks of
daily life. A third approach deﬁnes
acceptably low risks based on the risks
children face in daily life. Australia’s
guidelines categorize research interven-
tions as posing minimal risk when ‘‘the
probability and magnitude of harm or
discomfort anticipated in the research
are not greater in and of themselves
than those ordinarily encountered in
daily life’’ [18]. Guidelines from Nepal
[19] and the United States [20,21]
combine this deﬁnition with the rou-
tine examinations standard, deﬁning
minimal risks as ‘‘not greater in and of
themselves than those ordinarily en-
countered in daily life or during the
performance of routine physical or
psychological examinations or tests.’’
The ‘‘risks of daily life standard’’
would seem to allow children in war-
torn areas to be exposed to enormous
risks for the beneﬁt of others. Recog-
nizing this concern, the South African
Medical Research Council limits the
‘‘risks of daily life’’ standard to the risks
‘‘normally encountered in the daily
lives of people in a stable society’’ [22].
The risks of daily life standard pro-
vides an objective comparator for eval-
uating the risks of pediatric research,
thus avoiding the pitfalls of relying
exclusively on the individual judgment
of REC members. To implement this
standard effectively, RECs must distin-
guish the called-for comparison from
the comparisons appropriate to the
other two steps in the risk assessment
process.
Clarifying the Comparisons
Involved in the Risk Assessment
Process
Step 1: Identifying the research
interventions. Clinical studies often
involve both research and standard-
of-care interventions. To minimize the
number of interventions they need to
review, RECs can ﬁrst determine which
interventions qualify as research inter-
ventions (see Figure 1). The US federal
regulations, for example, direct RECs
to evaluate the risks of only the
research interventions, as opposed to
any ‘‘therapies subjects would receive
even if not participating in the re-
search.’’
This approach is based on the
assumption that any interventions par-
ticipating children otherwise would
undergo as part of their routine clinical
care have been determined to be
appropriate for them. Thus, RECs need
assess only those interventions that are
not part of the participating children’s
routine clinical care.
Tragically, children in developing
countries often do not receive any
routine medical care, including proven
effective treatments. As a result, an
intervention may qualify as a research
intervention when used in a developing
country, but not when it is part of a
study in a country where children
would receive the intervention even if
they did not participate in research.
While initially puzzling, this difference
makes sense. Standard treatments not
routinely provided in a particular set-
ting are likely not to have been assessed
for efﬁcacy and toxicity in that setting.
Hence, it makes sense for the reviewing
REC to assess these interventions care-
........................................................................................................................................................................................
Table 1. Standards for Defining Acceptably Low Risks in Pediatric Research
Standard Included in Concerns
No Research Risks to Children Nuremberg Code 1. Prohibits research necessary to ensure treatments safe and effective for children
German regulations of 1931
Left to Review Committee’s
Judgment
Council of Europe 1. Judgment of risks unreliable
Kenya 2. Wide variation across review committees
Indian Council of Medical Research
National Council for Science and Technology
Risks of Routine Examinations CIOMS 1. In developed countries, allows almost no risks
2. Seems inapplicable in many developing countries
3. Risks of routine procedures justified by benefits to children who undergo them
Risks of Activities of Daily Life Nepal 1. Seems to allow inappropriate risks in some cases
South African Research Council 2. Many risks of daily life justified by benefits to children who face them
US federal regulations
DOI: 10.1371/journal.pctr.0010025.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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tine medical care in other countries,
and may not need to undergo REC
review and approval.
Step 2: Determining the risk–beneﬁt
proﬁle of the research interventions.
The risks and beneﬁts posed by re-
search interventions can vary depend-
ing on the children who undergo them.
The risks of an MRI scan are very
different for children who suffer from
panic disorders compared with healthy
children. Since RECs must determine
the risk–beneﬁt proﬁle of pediatric
research procedures prospectively,
they cannot make this determination
for the speciﬁc children who will be
enrolled. Instead, the REC should assess
the risk–beneﬁt proﬁle of each re-
search intervention for the children
eligible for the study.
If the risk–beneﬁt proﬁle of some
i n t e r v e n t i o n sv a r i e ss i g n i ﬁ c a n t l yb y
different groups of children who are
eligible, the REC should determine the
risk–beneﬁt proﬁle for each of the
distinct groups. If the REC ﬁnds that
one or more groups faces signiﬁcantly
higher risks compared with other eligi-
ble children, it should consider exclud-
ing those who face greater risks.
Exclusion of children who face signiﬁ-
cantly higher risks makes sense espe-
cially when their participation is not
vital for scientiﬁc reasons, and the
study does not offer them an important
potential for clinical beneﬁt that is
unavailable outside the research con-
text.
The fact that a research intervention
offers participating children a potential
for clinical beneﬁt that compensates for
its risks does not imply that the inter-
vention is necessarily acceptable. In
some cases, the treatments participants
receive in research replace treatments
they otherwise would receive in the
clinicalsetting.Whenthishappens,RECs
shouldassesswhethertheresearchtreat-
ment offers a risk–beneﬁt proﬁle that is
at least as favorable as the available
alternatives, including not undergoing
the intervention at all.
To assess an intervention’s risk–
beneﬁt proﬁle, RECs should compare
it with the risk–beneﬁt proﬁle of the
available alternatives for the participat-
ing children. It follows that a given
research treatment may have a favor-
able risk–beneﬁt ratio when adminis-
tered in a developing country to
children who have no available alter-
natives, but an unfavorable risk–beneﬁt
ratio in a developed country that
provides children clinically indicated
treatment.
A number of authors have pointed
out that allowing some interventions to
be tested in developing countries but
not in developed countries raises the
potential for exploitation [23–25]. This
potential for exploitation could be
addressed by insisting that the risk–
beneﬁt proﬁle of research interventions
be compared with the risk–beneﬁt
proﬁle of the best interventions avail-
able anywhere in the world. This
solution implies that an experimental
treatment studied in a developing
country that offers a compensating
potential for clinical beneﬁt that is
better than any alternatives available
there nonetheless poses an unaccept-
able risk–beneﬁt ratio if the treatment
is not as good as the treatments used in
the developing world.
This approach has the potential to
deny deprived children effective treat-
mentsinthenameofprotectingthem.A
better approach would be to recognize
that the concern posed by such trials is
not the risk–beneﬁt proﬁle of the re-
searchinterventions,butthepotentialto
exploit individuals’ deprived circum-
stances. While beyond the scope of the
present paper, safeguards have been
proposed to address this type of exploi-
tation without altering the process of
risk assessment [26].
When the risk–beneﬁt proﬁle of a
research intervention is at least as
favorable as the available alternatives,
the intervention poses no net risks—
hence, it offers an ethically acceptable
risk–beneﬁt proﬁle. If the risk–beneﬁt
proﬁle of the intervention is less favor-
able than one or more of the available
alternatives, it poses ‘‘net’’ risks. The
magnitude of an intervention’s net risks
is determined by the extent to which it
presents increased risks, or a decreased
potential for clinical beneﬁt compared
DOI: 10.1371/journal.pctr.0010025.g001
Figure 1. Step Assessment of the Risks of Pediatric Research Interventions
*, including not undergoing the intervention at all; þ, ‘‘net’’ risks are determined by the extent to
which the risks exceed the potential for clinical benefit; #, some regulations allow RECs to approve
greater than minimal risk interventions when the risk is no more than a minor increase over
minimal and the study meets several other conditions.
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not undergoing the intervention at all.
Step 3: Assessing the ‘‘net’’ risks. The
‘‘risks of daily life’’ standard directs
RECs to assess the net risks of research
interventions by comparing them with
the level of risk ordinarily encountered
in daily life by average healthy children.
At this step in the risk assessment
process, the appropriate comparison
is between the risks the speciﬁc partic-
ipants face from the research interven-
tions and the risks average children
face in daily life (or during the per-
formance of routine examinations).
Importantly, to assess net risks, RECs
should not compare the interventions
included in the research with the
interventions the same children under-
go as part of their routine medical care.
For example, the fact that some chil-
dren routinely undergo a particular
type of biopsy as part of their clinical
care does not imply that the risks of
that type of biopsy are necessarily
minimal for them. In contrast, to
determine which interventions qualify
as research interventions in the ﬁrst
place, RECs do compare the interven-
tions included in the study under
review with the interventions the same
children would receive even if they did
not participate in research.
Example: Randomized trial of new
malaria treatment. To illustrate the
three-step risk assessment method,
consider how it would apply to a study
of a new treatment for childhood
malaria. Imagine that the study pro-
vides all participants with standard-of-
care treatment, and then randomizes
half of the participants to also receive
an experimental, add-on treatment. All
participants undergo a series of blood
draws, some for clinical care and a few
for research purposes. In addition, the
researchers propose to take a minimal
amount of extra blood for research
purposes during several of the clini-
cally indicated blood draws.
Step 1: Toassesstherisksofthisstudy,
the REC ﬁrst should determine which of
the interventions qualify as research
interventions, by comparing the study
interventions with the clinically indi-
cated interventions the same children
would receive even if they did not
participate in research. Since clinically
indicated treatment includes the stand-
ard medications and the clinically in-
dicated blooddraws, theseinterventions
do not qualify as research interventions.
Because participants would not receive
the experimental, add-on treatment, or
undergo the research blood draws in the
clinicalsetting,theseinterventionsqual-
ify as research interventions. For the
same reason, the collection of extra
blood during the clinically indicated
blood draws qualiﬁes as a research
intervention.
Step 2: In the second step, the REC
should assess the risk–beneﬁt proﬁle of
each of the research interventions for
the groups of children who are eligible
for the study. Whether the add-on
treatment can be categorized as offer-
ing a favorable risk–beneﬁt ratio will
depend on the nature and extent of
previous experience with the drug. At
this step, the REC should consider all of
the previous experience with the drug,
including whether it has been used to
treat other conditions, whether it has
been used in adults, and whether it has
ever been used in children with ma-
laria. In each case, the REC should
assess to what extent the previous
experience is relevant to the current
study, given the children who will be
enrolled, the doses to be used, and the
other medications that will accompany
the new treatment.
The add-on treatment may have a
synergisticeffect,providinggreaterbeneﬁt
in combination with the other treatments.
Alternatively, combining it with other
medicationsmaycreateagreaterpotential
for toxicity compared with the use of the
new treatment as a single agent. Taking
these possibilities into account, the REC
shoulddeterminewhethertheexperimen-
tal treatment offers a favorable risk–
beneﬁt ratio to participating children
and, if so, whether its risk–beneﬁt proﬁle
is at least as favorable as the available
alternatives. If it is, the treatment can be
approved as offering a compensating
potential for medical beneﬁt. If the treat-
ment offers a risk–beneﬁt proﬁle less
favorable than the available alternatives,
includingnotundergoingtheintervention
at all, it poses net risks.
Presumably, the research blood
draws and the extra blood drawn
during the clinically indicated blood
draws do not offer the potential for
clinical beneﬁt. Thus, the net risks of
these interventions are represented by
all the risks they pose to the participat-
ing children, taking into account their
overall clinical condition, as well as
how much total blood will be drawn
during the study period.
Step 3: To assess the acceptability of
an intervention’s net risks under the
risks of daily life standard, the REC
should compare the net risks that the
intervention poses to the children in
the study with the level of risks average
children face in daily life (or during
routine examinations). Notice that
comparing the interventions the chil-
dren receive in the study with the
interventions these same children re-
ceive routinely as part of their clinical
care raises the potential to exploit
those children who face greater risks
in their daily lives. For example, the
REC should not categorize the extra
blood draws as minimal risk simply on
the grounds that the participating
children happen to receive many blood
draws as part of their standard medical
care. Indeed, the fact that some chil-
dren receive many blood draws as part
of their standard medical care may well
increase the risks of the research blood
draws, for example, by increasing the
chances that the research blood draws
will induce anemia in these children.
Conclusions
Evaluation of the risks of pediatric
research involves several steps, each of
which requires a slightly different com-
parison. Clarifying the comparison ap-
propriate to each step should help RECs
to protect children and ensure that
advances in pediatric medicine are not
gained at the cost of exploiting some
children.
Becausemany,perhapsmostinterventions
in the research setting pose risks yet
offer some potential for clinical beneﬁt,
the concept of net risks is central to the
risk assessment process. This concept is
familiar to clinicians who often must
assess whether the potential beneﬁts of a
given treatment justify its risks. However,
in the clinical setting, interventions are
considered inappropriate if they pose
any net risks at all. In the research
setting, net risks may be acceptable if
they are sufﬁciently low. As a result,
RECs must make the more complicated
determination of estimating the magni-
tude of the net risks of a given inter-
vention. Future research should consider
different approaches that RECs might
use to estimate the magnitude of net
risks posed by research interventions. “
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